These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34177376)

  • 1. Joint modelling of longitudinal and survival data in the presence of competing risks with applications to prostate cancer data.
    Sheikh MT; Ibrahim JG; Gelfond JA; Sun W; Chen MH
    Stat Modelling; 2021 Feb; 21(1-2):72-94. PubMed ID: 34177376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New C-indices for assessing importance of longitudinal biomarkers in fitting competing risks survival data in the presence of partially masked causes.
    Sheikh MT; Chen MH; Gelfond JA; Sun W; Ibrahim JG
    Stat Med; 2023 Apr; 42(9):1308-1322. PubMed ID: 36696954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Bayesian multi-risks survival (MRS) model in the presence of double censorings.
    de Castro M; Chen MH; Zhang Y; D'Amico AV
    Biometrics; 2020 Dec; 76(4):1297-1309. PubMed ID: 31994171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian inference of the fully specified subdistribution model for survival data with competing risks.
    Ge M; Chen MH
    Lifetime Data Anal; 2012 Jul; 18(3):339-63. PubMed ID: 22484596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Joint modeling of multivariate longitudinal data and the dropout process in a competing risk setting: application to ICU data.
    Deslandes E; Chevret S
    BMC Med Res Methodol; 2010 Jul; 10():69. PubMed ID: 20670425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An approach to joint analysis of longitudinal measurements and competing risks failure time data.
    Elashoff RM; Li G; Li N
    Stat Med; 2007 Jun; 26(14):2813-35. PubMed ID: 17124698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian Model Assessment in Joint Modeling of Longitudinal and Survival Data with Applications to Cancer Clinical Trials.
    Zhang D; Chen MH; Ibrahim JG; Boye ME; Shen W
    J Comput Graph Stat; 2017; 26(1):121-133. PubMed ID: 28239247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A two-level copula joint model for joint analysis of longitudinal and competing risks data.
    Lu X; Chekouo T; Shen H; de Leon AR
    Stat Med; 2023 May; 42(12):1909-1930. PubMed ID: 37194500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing Importance of Biomarkers: a Bayesian Joint Modeling Approach of Longitudinal and Survival Data with Semicompeting Risks.
    Zhang F; Chen MH; Cong XJ; Chen Q
    Stat Modelling; 2021 Feb; 21(1-2):30-55. PubMed ID: 34326706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian nonparametric mixed-effects joint model for longitudinal-competing risks data analysis in presence of multiple data features.
    Lu T
    Stat Methods Med Res; 2017 Oct; 26(5):2407-2423. PubMed ID: 26265770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A general joint model for longitudinal measurements and competing risks survival data with heterogeneous random effects.
    Huang X; Li G; Elashoff RM; Pan J
    Lifetime Data Anal; 2011 Jan; 17(1):80-100. PubMed ID: 20549344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hierarchical models for semi-competing risks data with application to quality of end-of-life care for pancreatic cancer.
    Lee KH; Dominici F; Schrag D; Haneuse S
    J Am Stat Assoc; 2016; 111(515):1075-1095. PubMed ID: 28303074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian joint modeling of ordinal longitudinal measurements and competing risks survival data for analysing Tehran Lipid and Glucose Study.
    Baghfalaki T; Kalantari S; Ganjali M; Hadaegh F; Pahlavanzadeh B
    J Biopharm Stat; 2020 Jul; 30(4):689-703. PubMed ID: 32129702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Joint modelling with competing risks of dropout for longitudinal analysis of health-related quality of life in cancer clinical trials.
    Cuer B; Conroy T; Juzyna B; Gourgou S; Mollevi C; Touraine C
    Qual Life Res; 2022 May; 31(5):1359-1370. PubMed ID: 34817733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A joint model of longitudinal and competing risks survival data with heterogeneous random effects and outlying longitudinal measurements.
    Huang X; Li G; Elashoff RM
    Stat Interface; 2010; 3(2):185-195. PubMed ID: 21892381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An issue of identifying longitudinal biomarkers for competing risks data with masked causes of failure considering frailties model.
    Ko FS
    Stat Methods Med Res; 2020 Feb; 29(2):603-616. PubMed ID: 30991892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Bayesian approach to joint analysis of longitudinal measurements and competing risks failure time data.
    Hu W; Li G; Li N
    Stat Med; 2009 May; 28(11):1601-19. PubMed ID: 19308919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A two-stage model in a Bayesian framework to estimate a survival endpoint in the presence of confounding by indication.
    Bellera C; Proust-Lima C; Joseph L; Richaud P; Taylor J; Sandler H; Hanley J; Mathoulin-Pélissier S
    Stat Methods Med Res; 2018 Apr; 27(4):1271-1281. PubMed ID: 27587597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Joint modeling of longitudinal zero-inflated count and time-to-event data: A Bayesian perspective.
    Zhu H; DeSantis SM; Luo S
    Stat Methods Med Res; 2018 Apr; 27(4):1258-1270. PubMed ID: 27460540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.